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Abstract
Objectives: To assess the incidence and to review experience with the treatment of mucosal melanoma of the
head and neck (MMHN) in Slovenia between 1985 and 2013.
Methods: The National Cancer Registry database and clinical records with outcome data of identified patients
treated during the period 1985–2013 in Slovenia were reviewed.
Results: In a 29-year period, 61 patients with MMHN were identified, representing 0.5 % of all head and neck
malignant tumors and 42 % of all mucosal melanomas in Slovenia. 72 % originated in the sinonasal tract and
were predominantly (78 %) diagnosed as a local disease. Regional metastases at diagnosis were more frequent in
patients with oral/oropharyngeal primary (44 %; sinonasal MMHN 11 %, p = 0.006). Curative intent treatment was
given to 48 (79 %) patients. The overall survival (OS) rates at 2 and 5 years for the whole cohort were 43 % and
18 %, respectively, and for the curative intent group 53 % and 24 %, respectively. In the latter group, multivariate
analyses showed postoperative radiotherapy (PORT) to be predictive for locoregional control (LRC) (hazard ratios
[HR] for surgery with PORT vs. surgery alone: 1.0 vs. 3.9, p = 0.037), whereas only the World Health Organization
performance status (HR for grade 0 vs. grade 1 vs. grade >1: 1.0 (p = 0.022) vs. 1.2 (p = 0.640) vs. 7.7 (p = 0.008))
significantly influenced OS.
Conclusions: MMHN is a rare tumor with a poor prognosis. Combination of surgery and PORT offers the best
prospects for LRC but without improvement of OS. Due to potential toxicity of high-dose RT such treatment is
indicated in patients in whom LRC outweighs the risks of serious adverse effects.
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Introduction
Mucosal melanoma of the head and neck region (MMHN)
was first described by Weber in 1856 and has since been
the subject of an increasing number of retrospective
studies while its rareness precluded any prospective
trials [1]. The yearly incidence of mucosal melanoma is
2.2–2.6 cases per million and approximately half of the
cases appear in the upper part of the aerodigestive tract
[2–4]. Higher MMHN incidence was reported in Japan
and Uganda, although the ratio of MMHN vs. all mucosal
melanomas seems to be the same for Caucasians and the
Japanese [5, 6].
Malignant melanomas derive from melanocytes or
their precursor cells arising from the neural crest [7].
Contrary to its cutaneous counterpart, strong evidence
of environmental risk factors for the development of
mucosal melanoma is lacking and the possible role of
premalignant lesions remains to be elucidated as well
[8]. Diagnosis of pigmented MMHN is usually unam-
biguous, however, it can be difficult to obtain in amelanotic
and ulcerated lesions [9]. Regardless of treatment, overall
survival (OS) in MMHN is poor and rarely do 5-year OS
rates exceed 30 % [8]. It is generally agreed upon that
radical surgical resection of the primary tumor offers the
best chance of local control and cure, whereas the role of
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elective neck resection and adjuvant-postoperative radio-
therapy (PORT) is not well established [8].
In the present study we sought to describe the inci-
dence of MMHN in Slovenia for the period from 1985
to 2013, to report our experience with these patients,
and to assess the significance of previously proposed
prognostic factors.
Patients and methods
Patient and tumor characteristics
Patients diagnosed from 1985 through 2013 with MMHN
in Slovenia were eligible for this nationwide population-
based retrospective study. In total, 61 consecutive pa-
tients were identified by the Cancer Registry database, a
population-based cancer registry covering the entire
Slovenian population since 1950 [10].
Epidemiological and clinical parameters are presented
in Table 1. Tumors were most frequently located in the
sinonasal tract (SN) (44 patients, 72 %) with subsites of
origin as follows: nasal cavity (33 patients, 54 %), maxillary
sinus (6 patients, 9.8 %), ethmoid sinus (3 patients, 4.9 %)
and nasopharynx (2 patients, 3.3 %). Sixteen tumors
(26 %) originated from the oral cavity (14 patients, 23 %)
and oropharynx (2 patients, 3.3 %) (OC-OP). One patient
presented with MMHN of the middle ear.
At presentation, localized disease was found in 48
patients (789 %) with 21 (44 %) tumors staged as T3, 22
(46 %) as T4a and 5 (10 %) as T4b (UICC TNM, 7th ed.).
Twelve patients (20 %) presented with positive cervical
lymph nodes (CLN) and three patients (4.9 %) were diag-
nosed with distant metastases: one of these patients had
lung metastases, while the other two presented with meta-
static spread to multiple sites (Table 1). Presenting symp-
toms and initial diagnostic work-up are summarized in
Table 2.
Treatment
Forty-eight patients (79 %) were treated with curative
intent, nine (14.8 %) received palliative treatment and
four (6.6 %) had only symptomatic treatment.
Treatment of primary tumor
In the curative intent group, the first-line therapy was
surgery in 37 patients (77 %) and definitive RT in 11
(23 %). There was no statistically significant difference
either in TNM stage distribution or in World Health
Organization performance status (WHO PS) between
these two groups. Surgery was either open (22 patients,
59 %) or endoscopic (15 patients, 41 %) with clear
margins achieved in 31 cases (84 %). PORT was delivered
in 16 (43 %) patients, from 20 to 65 days after surgery
(median, 45 days) (Table 1). In five cases the indications
for adjuvant RT to the primary tumor bed were positive
margins of resection, while in the other 11 cases the
decision for adjuvant RT was based on SN localization
(7 cases), high local disease burden (pT4, seven pa-
tients) or regional spread (pN+, three patients). Six out
of 11 primarily irradiated patients had a complete re-
sponse locally (assessed 8 to 12 weeks after RT by local
clinical examination only), four had a partial response
and one patient was declared a non-responder. No patient
was surgically salvaged, the reasons being an inoperable
disease or the patient's general condition being deemed
unsuitable for surgery. In the PORT and definitive RT
groups the equivalent RT doses to the primary tumor site
in 2-Gy fractions (EQD2, α/β = 2 Gy) [11] ranged from
45.0 to 72.0 Gy (median, 60.0 Gy) and from 52.5 to
75.0 Gy (median, 68.8 Gy), respectively. RT was delivered
using conventional fractionation of five 2.0–3.0 Gy frac-
tions (median, 2.0 Gy) per week in 17 cases, and hypo-
fractionation of 2–3 weekly fractions of 4.0–6.0 Gy
(median, 6.0 Gy) in 10 cases.
Treatment of neck
Eight patients had neck dissection, of whom six had
clinically palpable CLN; metastatic nodes were found
in all six patients. Four of these patients had PORT
(45.0–66.0 Gy, median 65.0 Gy) due to pN+ disease
(three patients, two with extracapsular tumor spread)
and synchronous squamous cell carcinoma of the tongue
base spreading to the CLN (1 patient). In patients without
neck surgery, CLN were irradiated in six cases, four of
them having had bilateral RT (63.0–72.0 Gy, median
70.0 Gy). Two of these patients had clinically positive CLN;
complete and partial response was clinically recorded after
RT in one patient each.
Radiotherapy technique
Two-dimensional computer planning, three-dimensional
conformal technique (3D-CRT) and intensity-modulated
technique (IMRT) were employed in 15 (56 %), eight
(30 %) and three (11 %) patients, respectively, whereas in
one patient RT was delivered by direct opposing field
(3.7 %). RT was delivered by a 12 MeV electron beam,
megavoltage cobalt-60 and 5–10 MV photon beams in
one, six and 20 patients, respectively. After the year 2007,
3D-CRT and IMRT were introduced (and cobalt-60
irradiation was abandoned) in all the patients receiving
radiotherapy.
Adjuvant systemic therapy
It was administered to 10 patients treated with curative in-
tent (21 %). In 6/10 low-dose interferon α-2b (3 million
IU i.m., three times/week for 25–60 weeks) was given after
the primary operation, two patients had chemotherapy
(vinblastine-lomustine-cisplatin, three cycles; dacarbazine,
nine cycles) after RT and two patients were treated with
concurrent PORT and low-dose interferon α-2b.
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Table 1 Epidemiological and clinical parameters of 61 patients with MMHN diagnosed in Slovenia, 1985–2013
Characteristic All cases Sinonasal tract Oral cavity & oropharynx p-value
N = 61 (%) N = 44 (%) N = 16 (%)
Age at diagnosis (years)
Median 75.5 77.0 68.2 0.059
Range 25.9–91.8 40.0–91.8 25.9–87.3
Sex
Male 32 (53) 20 (46) 11 (69) 0.110
Female 29 (48) 24 (55) 5 (31)
PS WHO
Grade 0 29 (48) 18 (41) 10 (63) 0.276
Grade 1 23 (38) 18 (41) 5 (31)
Grade >1 9 (15) 8 (18) 1 (6.3)
Duration of symptoms (months)
Median 2.0 2.0 1.0 0.554
Range 0.0–12.0 0.0–12.0 0.0–12.0
Tumor pigmentation
Yes 36 (59) 23 (52) 13 (81) 0.165
No 13 (21) 11 (25) 2 (13)
Unknown 12 (20) 10 (237) 1 (6.3)
Overall stage
1 48 (79) 38 (86) 9 (56) 0.029
2 10 (16) 4 (9.1) 6 (38)
3 3 (4.9) 2 (4.5) 1 (6.3)
TNM stage
III 21 (34) 16 (36) 4 (25) 0.203
IVA 30 (49) 19 (43) 11 (69)
IVB 7 (12) 7 (16) 0 (0.0)
IVC 3 (4.9) 2 (4.5) 1 (6.3)
Treatment intent
Curative 48 (79) 33 (75) 14 (88) 0.299
Palliative 13 (21) 11 (25) 2 (13)
Surgery
No 22 (36) 20 (46) 2 (13) 0.019
Yes 39 (64) 24 (55) 14 (88)
Open surgery 24 (62) 10 (42) 13 (93) 0.002
Endoscopic surgery 15 (39) 14 (58) 1 (7.1)
Radiotherapy
No 28 (46) 21 (48) 7 (44) 0.785
Yes 33 (54) 23 (52) 9 (56)
Definitive 11 (33) 9 (39) 2 (22) 0.066
Postoperative 16 (49) 8 (35) 7 (78)
Palliative 6 (18) 6 (26) 0 (0.0)
Systemic therapy
Yes 13 (21) 10 (23) 3 (19) 0.741
No 48 (79) 34 (77) 13 (81)
2-year overall survivala 43 (30–55) 40 (26–55) 54 (29–79) 0.548
5-year overall survivala 18 (7.8–29) 20 (7.4–32) 15 (0.0–35) 0.548
a% (95 % confidence interval). N Number of patients
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Palliative treatment
It was offered to nine patients and consisted of either local
excision or debulking of the primary tumor (2 patients),
palliative RT (6 patients, EQD2 24–68 Gy, median
53.6 Gy) or systemic therapy only (1 patient).
Statistical analyses
The study protocol was approved by the Protocol
Review Board of the Institute of Oncology Ljubljana
(ERID-KESOPKR/47).
The survival times were calculated from the start of
treatment and were censored at the close-out date
(February 15th 2015). The end points considered were
local control (LC), regional control (RC), locoregional
control (LRC), distant metastasis-free survival (DMFS),
and OS (death from any cause considered as an event).
The Kaplan-Meier method was used for univariate ana-
lysis of survival estimates and the differences between
potential prognostic groups were tested by a log-rank
test with 95 % confidence intervals (CI) reported. The
hazard ratio (HR) calculations and multivariate analysis
of significant prognostic factors from univariate analysis
were performed by the Cox proportional hazard regres-
sion model. The number of covariates to be included in
the multivariate analysis was determined according to
Peduzzi et al. recommending 10 events per variable




In the 29-year period from 1985 to 2013, MMHN repre-
sented 0.5 % of all head and neck malignancies, 0.8 % of all
melanomas, 4.4 % of all melanomas in the head and neck
region and 42 % of all mucosal melanomas in Slovenia.
Follow-up
The length of the follow-up period for all 61 patients
ranged from 0.9 to 190.2 months (median, 16.5 months),
and 22.5 months (range, 0.9–190.2 months) and 8.8 months
(range, 1.6–25.7 months) for those treated with curative
and palliative intent, respectively.
Patterns of failure
Out of 48 patients treated with curative intent, 15 (31 %)
patients eventually failed locally. The median time to local
recurrence was 15.4 months (range, 3.4–69.2 months) and
to regional recurrence, diagnosed in eight patients (17 %;
5/8 patients had no treatment to the neck) 7.7 months
(range, 3.4–106.3 months) after the start of the treatment.
The 2- and 5-year LRC rates were 52 % (95 % CI 36–69)
and 27 % (95 % CI 7.6–46), respectively. Within the group
of operated patients the improvement in LRC with the
addition of PORT was significant (p = 0.019) with LRC at
2 years in operated-only patients and those with PORT
being 43 % (95 % CI 18–68) and 84 % (95 % CI 64–100),
respectively, and at 5 years 18 % (95 % CI 0–40) and 67 %
(95 % CI 33–100), respectively.
Systemic disease eventually developed in 24 (50 %)
patients 0.9 to 145.5 months after therapy (median,
11.8 months; 95 % CI 4.2–23). The DMFS rates at 2
and 5 years were 58 % (95 % CI 42–73) and 40 % (95 %
CI 22–57).
Table 2 Presenting symptoms and initial diagnostic work-up
Presenting symptoms No. of patients (%)
Epistaxis 20 (33)
Evident mass or swelling 18 (30)
Nasal obstruction 17 (28)
Pain 3 (4.9)
Regional non-nasal bleeding 2 (3.3)
Hearing impairment 2 (3.3)
Headache 1 (1.6)
Dysphagia 1 (1.6)
Signs of metastatic disease 1 (1.6)
No symptoms reported 17 (28)








Sinus X-ray 5 (8.2)





Clinical examination only 29 (48)
Distant metastatic spread
Chest X-ray 45 (74)
Abdominal US 31 (51)
Bone scan 4 (6.6)
Thoracic CT 3 (4.9)
PET-CT 3 (4.9)
Head CT 1 (1.6)
Clinical examination only 12 (20)
CT Computer tomography, MRI Magnetic resonance imaging, US Ultrasonography,
PET Positron emission tomography
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Several prognostic factors were confirmed to be statisti-
cally significant on univariate analysis in terms of influen-
cing the LC, LRC, and DMFS (Table 3). In multivariate
analysis, only treatment modality appeared significant for
predicting LC (Fig. 1, Table 4).
Survival and prognosis
In curative intent treatment group, salvage therapy was
offered to 23 out of 30 patients (77 %) with recurrent
disease, of whom nine were treated more than once. At
the close-out date, 38 patients (79 %) had died of MMHN,
five (10 %) were alive and free of MMHN, and four had
died of other causes (with persistent MMHN occurring in
one patient). For one patient the vital status was unknown.
The OS ranged from 0.9 to 190.2 months (median,
25.4 months; 95 % CI 2.5–48). The OS rates at 2 and
5 years were 53 % (95 % CI 39–67) and 24 % (95 % CI
11–36), respectively. Univariate analysis showed a sig-
nificant impact of age (p = 0.036), PS WHO (p < 0.001)
and systemic therapy (p = 0.011) on OS (Table 3). Besides
these, treatment modality as a clinically relevant factor
with marginal significance (p = 0.074) in univariate ana-
lysis was also introduced into the Cox multivariate
model. However, only PS WHO was retained in the
model (Table 4).
For the whole cohort of 61 patients, the OS rates at 2
and 5 years were 43 % (95 % CI 30–55) and 18 % (95 %
CI 7.8–29), respectively.
Table 3 Univariate analysis
Prognostic factor Outcome (p-value )*
LC LRC DMFS DSS OS
Age (years)
< 65 vs. >65 0.188 0.135 0.083 0.074 0.036
Sex
Male vs. Female 0.674 0.241 0.425 0.276 0.189
Performance status (WHO)
0 vs. 1 vs. 2 + 3 + 4 0.034 0.095 0.860 <0.001 <0.001
Site
SN vs. OC-OP 0.125 0.056 0.291 0.581 0.768
Pigmented lesion
Yes vs. No 0.888 0.953 0.157 0.329 0.246
T-stage
T3 vs. T4A/B 0.752 0.931 0.643 0.291 0.226
N-stage
N0 vs. N+ 0.612 0.650 0.892 0.741 0.742
TNM-stage
III vs. IVA/B 0.595 0.708 0.807 0.382 0.315
Year of first treatment
1985–2007 vs. 2008–2013 0.926 0.286 0.860 0.777 0.916
Treatment modality
Surgery vs. RT vs. surgery + PORT <0.001 <0.001 0.796 0.111 0.074
Systemic therapy
Yes vs. No 0.858 0.376 0.036 0.022 0.011
Failure of local control
Yes vs. No NA NA 0.994 0.802 0.905
Failure of regional control
Yes vs. No 0.720 NA 0.498 0.636 0.472
Failure of distant control
Yes vs. No 0.741 0.434 NA 0.088 0.234
*Regional control was not used in Kaplan-Meier calculations due to low number of events (N = 8).
LC Local control, RC Regional control, LRC Locoregional control, DMFS Distant metastasis-free survival; DSS Disease-specific survival, OS Overall survival, WHO World
Health Organization, SN Sinonasal, OC-OP Oral cavity/oropharynx, RT Radiotherapy, PORT Postoperative radiotherapy, NA Not applicable
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Long-term survivors
Nine out of 48 patients (19 %; six females and three
males, from 28.6–77.8 years of age, median 75.5 years)
survived for 5 years or more after being diagnosed with
MMHN, of whom three lived 12.1, 13.8 and 15.9 years
after diagnosis. The origin of primary tumors was the
nasal cavity in seven cases and oral cavity in two cases.
Primary tumor stage at diagnosis was T3 in five and
T4a in four cases; one patient was presented with re-
gional metastases. All patients had up-front surgery
Fig. 1 Impact of treatment modalities on local and locoregional control. S – surgery, RT – radiotherapy, SRT – surgery and postoperative radiotherapy
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(endoscopic – 6, open – 3) with clear margins achieved
in all cases. One patient had unilateral elective dissec-
tion of regions I-II and in another patient bilateral
dissection was done due to clinically evident CLN me-
tastases (regions I-V). PORT was implemented in two
cases. Disease recurred in six patients: two of them had
isolated local recurrence 41 and 51 months after the
first treatment and were successfully salvaged by addi-
tional surgery with PORT in one case. The other four
patients had more than one failure. Six of the long-
term survivors eventually died of MMHN.
Discussion
In the present study, surgery followed by PORT resulted
in the most favorable LRC compared to surgery alone or
RT alone. In view of no survival advantage of combined
therapy observed in our patients and significant lack in
the use of comprehensive pre- and post-RT imaging
(CT/MR), we recommend PORT only to selected pa-
tients at increased risk of recurrence in surgical field.
The incidence of MMHN in Slovenia (1.1 per million
per year) is in line with the published data from Europe
and the USA and does not appear to be rising [2–4, 10].
Also, other epidemiological data are within the frames of
comparable preceding reports [13–16]. MMHN's predi-
lection to occur in the nasal cavity and paranasal sinuses
compared to the oral cavity and oropharynx was con-
firmed in the present series, yet no explanation of this
difference has thus far been validated [8]. In the present
series, the mode of primary treatment did indeed affect
the course of the disease. The most favorable outcome
in terms of LC and LRC was achieved by combining
surgery and RT (Fig. 1, Table 4), although with no sur-
vival advantage observed. Therefore, potential toxicity of
high-dose RT should always be taken into account and
such treatment offered only to selected patients where
LRC outweighs the risks of serious adverse effects.
The efficacy of RT in MMHN has been thus far
analyzed in a number of series and it seems that both
definitive RT and PORT improve local control [17]. In
particular, high-linear energy transfer radiation appears
to be comparable to surgery in maintaining local con-
trol in MMHN [18]. Both positive and close margins,
difficult-to-access SN sites with a high probability of re-
sidual disease as well as multiple positive nodes and
extracapsular tumor spread warrant adjuvant irradiation
[17]. In our patients photon/electron RT to the site of the
primary tumor was employed in 27 (56 %) curative-intent
Table 4 Multivariate analysis
Prognostic
factora
LC LRC DMFS OS
HR (95 % CI) p-value HR (95 % CI) p-value HR (95 % CI) p-value HR (95 % CI) p-value
Age (years)
<65 NI NI 1.0 1.0
>65 1.2 (0.40–3.4) 0.793 0.89 (0.31–2.6) 0.836
Performance status (WHO)
0 1.0 0.523 1.0 0.473 NI 1.0 0.022
1 0.73 (0.24–2.2) 0.576 0.61 (0.23–1.6) 0.315 1.2 (0.52–2.9) 0.640
2+3+4 1.9 (0.31–12) 0.483 1.4 (0.25–7.6) 0.722 7.7 (1.7–34) 0.008
Site
SN 2.1 (0.52–8.7) 0.298 2.1 (0.64–7.4) 0.216 NI NI
OC-OP 1.0 1.0
Pigmented lesion
Yes NI NI 1.0 NI
No 1.2 (0.40–3.4) 0.779
Treatment modality
Surgery 2.2 (0.42–12) 0.355 4.7 (0.98–22) 0.054 NI 1.0 (0.46–2.2) 0.979
RT 11 (2.1–63) 0.005 16 (3.0–80) 0.001 2.0 (0.73–5.5) 0.175
surgery+PORT 1.0 0.005 1.0 0.002 1.0 0.303
Systemic therapy
Yes NI NI 1.0 1.0
No 2.6 (0.62–11) 0.193 3.1 (0.92–10) 0.068
aFactors with no statistical significance in univariate analysis were included if deemed clinically relevant
NI not included in multivariate analysis, LC Local control, LRC Locoregional control, DMFS Distant metastasis-free survival, OS Overall survival, WHO World Health
Organization, SN Sinonasal, OC-OP Oral cavity/oropharynx, RT Radiotherapy, PORT Postoperative radiotherapy
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Table 5 Mucosal melanoma of the head and neck: a review of the recent literature series (with ≥50 patients & utilizing radiotherapy)






TNM stage (%) Treatment
modality (%)
OS
(at 5 years, %)
DSS,
(at 5 years, %)Median/Mean*
(range)
Gal et al., 2011 [29] Population-based
(26 %), USA
2000–2007 304 71.2* SN, all III, 32.2 S, 43.1 24.2 NR
IVA, 25.3 SRT, 38.5
IVB, 11.2 RT, 7.6
IVC, 12.2 None/Unknown, 10.9
Jangard et al., 2013 [13] Population-based
(96 %), Sweden
1960–2000 186 72 (31–93) SN, all I, 83.9 S, 53.1 NR 20.4
II, 2.2 SRT, 32
III, 4.3, SRTSTh, 2.7
Unknown, 9.7 Palliative, 12.2
Benlyazid et al., 2010 [30] Multi-institutional,
France
1980–2008 160 67.0 (30–93) SN, 90.6 I, 96.3 S, 51.3 37.5 NR
OC, 7.5 II, 3.8 SRT, 48.8
Other, 1.9




Shiga et al., 2012 [31] Multi-institutional,
Japan
1998–2007 94 68.4* (37–96) SN, 78.7 I, 16.0 S, 9.6 S + STh/RT, 38.6 NR
OC-OP, 15.6 II, 28.7 RT, 9.6 RT+/−STh, 29.9
Unknown primary,
3.2 External ear, 2.1
III, 9.6 STh, 7.4
IVA, 31.9 S + STh/RT, 52.1
IVB, 3.2 RT+/−STh, 19.1
IVC, 10.6 None, 2.1
Meng et al., 2014 [32] Single institution,
China
2000–2010 69 65.9* (28–89) SN, all III, 53.6 S, 39.1 S, 31.6 NR
IVA, 39.1 SRT, 34.8 SRT, 55
IVB, 7.2 SRTSTh, 26.1 SRTSTh, 32.1
Sun et al., 2014 [33] Single institution,
China
1976–2005 68 55 (2–79) SN, all III, 52.9 S, 27.7 29.7 NR
IVA, 35.3 RT, 6.2
IVB, 5.9 STh, 12.3
IVC, 5.9 SRT, 20.0
S + STh, 29.2












Table 5 Mucosal melanoma of the head and neck: a review of the recent literature series (with ≥50 patients & utilizing radiotherapy) (Continued)
Douglas et al., 2010 [34] Single institution, UK 1965–2001 68 63 (29–86) SN, 65 I, 80 S, 27 22 32
OC, 19 II, 19 RT, 46
Other, 16 III, 1 SRT, 7
Palliative, 20
Demizu et al., 2014 [35] Single institution,
Japan
2003–2011 62 70.5 (33–89) SN, 90.3 T1, 27 RT, all At 1 year, 93 NR
OC, 9.7 T2, 31 - protons, 53.2 At 2 years, 61
T3, 31 - carbon ion, 46.8
T4, 11 Prior treatment:
S, 11.3
STh, 8.1
S + STh, 3.2
Moreno et al., 2010 [19] Single institution,
USA
1993–2004 58 63.4 (38–93) SN, all I, 87.9 S, 43.1 38.7 18.4
II, 6.9 SRT, 53.4
III, 5.2 RT, 3.4
Shuman et al., 2011 [28] Single institution,
USA
1992–2009 52 66* OC, 31 I, 25.0 S, 69.2 38 22
SN, 69 II, 34.6 SRT, 19.2
III, 11.5 Palliative RT, 9.6
IV, 28.8
Sun et al., 2012 [36] Single institution,
China
1976–2005 51 55 (31–75) OC, all III, 23.5 S, 76.5 20.7 NR
IVA, 34 SRT, 3.9
IVB, 4 STh, 11.8
IVC, 1 None, 7.8
Koivunen et al., 2012 [37] Multi-institutional,
Finland
1990–2004 50 70* (46–93) SN, all III, 36 S, 66.0 27 48
IVA, 42 SRT, 14.0
IVB, 20 RT, 14.0
IVC, 2
Current series, 2016 Population-based,
Slovenia
1986–2013 61 75.5 (25–91) SN, 72 III, 34 Curative intent Whole cohort, 18
Curative intent, 24
Curative intent, 25
OC-OP, 26 IVA, 49 (N = 48):
Middle ear, 1.6 IVB, 12 S, 44
IVC, 4.9 SRT, 33
RT, 23
OS Overall survival, SN Sinonasal tract, S Surgery, SRT Surgery and postoperative radiotherapy, RT Radiotherapy, NR Not reported, SRTSTh Surgery with postoperative radiotherapy and systemic therapy, OC Oral cavity,












patients with the neck irradiated in 10 of these patients to
the median EQD2 of 68.8 Gy (definitive setting) and
60.0 Gy (PORT setting). The herein confirmed positive
impact of high dose PORT (>54 Gy) on LRC has been
previously suggested by Moreno et al. [19] In regard to
fractionation pattern, the optimal schedule is unclear: con-
ventional fractionation is widely accepted (it was used in
18/27 of our patients) whereas clinical utility of hypo-
fractionation, despite being radiobiologically superior to
melanoma cells, seems to be limited in the head and
neck region by proximity of important normal tissues
sensitive to higher fraction doses [20].
Considering the low rate of spread to the CLN, we ad-
vocate elective neck dissection only for selected patients
with a high local disease burden or with a primary tumor
located in or extending to the oral cavity or oropharynx.
In the present series, of 12/61 patients presenting with
clinically positive CLN, six had neck dissection (pN+
disease confirmed in all cases) and two received defini-
tive neck irradiation. Besides these, two patients with
pT4a tumors and without clinically positive CLN were
treated with neck dissection as well, both being classi-
fied as pN0. Overall, of 48 patients treated with curative
intent 17 % later relapsed in the CLN. However, this
figure must be interpreted with caution, because as
much as 48 % of the patients had only clinical examin-
ation of the neck performed during primary diagnos-
tics. In the literature, there has been much controversy
over elective treatment of CLN. The latter is supported
by some authors [15, 21] while others oppose elective
neck dissection in MMHN because of low rates of posi-
tive CNL and regional recurrences, proposing only a
wait-and-see policy [22]. An appealing approach to
clarify the need for elective neck dissection in MMHN
patients is sentinel lymph node biopsy, which is an
already well established diagnostic tool in cutaneous
malignant melanoma. As only case reports on this sub-
ject have been published so far [23], further research is
needed to determine its value in diagnostic algorithms
for MMHN.
A combination of immunotherapy and chemotherapy
(biochemotherapy) has previously showed considerable
response rates and favorable effect on progression-free
interval but with no impact on OS [24]. Our data from
multivariate analysis, controlled for age, PS WHO and
treatment modality, confirm the lack of effect of sys-
temic treatment on survival. However, new targeted
drugs are constantly being developed and their effect
on disease course seems more promising. Taking into
account results from cutaneous melanoma studies, the
minority of MMHN patients with driver mutations of
oncogenes could benefit from KIT and BRAF inhibitors
[25, 26]. The aggressive behavior of MMHN presents a
great challenge to clinicians. Even in the era of advanced
diagnostic and treatment options prognosis remains
dismal and little progress in the outcome of these pa-
tients was observed. In 1998 Chang et al. reported on
212 MMHNs, diagnosed between 1985 and 1989, with
a 5-year overall survival rate of 31.7 % which is not notably
worse than most favorable results reported in the more re-
cent series (Table 5) [3, 13, 19, 27–37]. These results sug-
gest that at least a temporary plateau has been reached
concerning survival. The herein presented results of multi-
variate analyses of survival possibly reflect this finding, as
only performance status was found to be an independent
prognosticator of OS. More advanced surgical and irradi-
ation techniques used in more recent series probably re-
sulted in improved treatment-related toxicity profile,
contributing to less detrimental effect on post-treatment
quality of life [32]. Nine patients in the present series who
survived more than 5 years (3/9 lived more than 10 years)
after diagnosing MMHN confirm the potential of achieving
long survival times in MMHN. The retrospective nature of
the present and previously published MMHN series is in-
herent to rare cancer studies. This results in notable treat-
ment selection bias which in turn hampers analyses of
prognostic factors. Furthermore, the majority of MMHN
series are single- or multi-institutional, leading to possible
referral bias. In contrast, the present series is a population-
based study and as such offers to fill this potential data
gap. In addition, we performed controlled, multivariate
analyses of prognostic factors, further contributing to the
quality of the presented results.
Conclusions
MMHN is a rare cancer with a stable incidence of far
below two cases per million. For this reason, unbiased data
on the optimal treatment is lacking. However, MMHN's
propensity to recur even after radical surgical treatment is
well known and this dictates the need for aggressive adju-
vant treatment. The results presented herein support the
use of high-dose PORT in selected patients in whom LRC
is deemed worth the side effects. The roles of elective
treatment of the CLN and of systemic treatment remain
to be elucidated.
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